{
    "ticker": "TGTX",
    "name": "TGTX, Inc.",
    "description": "TGTX, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for patients with cancer and autoimmune diseases. Established in 2010, TGTX aims to provide effective treatment options that address significant unmet medical needs. The company\u2019s leading candidates include monoclonal antibodies targeting various mechanisms of action to disrupt disease progression. TGTX is currently advancing the development of its flagship product, ublituximab, a next-generation anti-CD20 monoclonal antibody, which is undergoing clinical trials for treating chronic lymphocytic leukemia (CLL) and other hematological malignancies. In addition to ublituximab, TGTX is also developing other pipeline candidates that target autoimmune disorders, showcasing the company\u2019s commitment to addressing a broad range of diseases. The company prioritizes patient-centric approaches in its research and development, collaborating with healthcare providers and institutions to ensure its therapies meet the needs of patients. TGTX is headquartered in Newport Beach, California, and is dedicated to advancing science and improving patient outcomes through innovation. With a focus on precision medicine, TGTX seeks to deliver therapies that can transform treatment paradigms in oncology and beyond.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Newport Beach, California, USA",
    "founded": "2010",
    "website": "https://www.tgtxinc.com",
    "ceo": "Dr. Lee Morley",
    "social_media": {
        "twitter": "https://twitter.com/TGTXInc",
        "linkedin": "https://www.linkedin.com/company/tgtx-inc/"
    },
    "investor_relations": "https://www.tgtxinc.com/investors",
    "key_executives": [
        {
            "name": "Dr. Lee Morley",
            "position": "CEO"
        },
        {
            "name": "Dr. Steven D. Ginsberg",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Monoclonal Antibodies",
            "products": [
                "Ublituximab"
            ]
        },
        {
            "category": "Pipeline Candidates",
            "products": [
                "TG-1701",
                "TG-1801"
            ]
        }
    ],
    "seo": {
        "meta_title": "TGTX, Inc. | Innovative Biopharmaceutical Solutions",
        "meta_description": "Learn about TGTX, Inc., a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for cancer and autoimmune diseases.",
        "keywords": [
            "TGTX",
            "Biopharmaceutical",
            "Monoclonal Antibodies",
            "Cancer Therapy",
            "Autoimmune Diseases",
            "Ublituximab"
        ]
    },
    "faq": [
        {
            "question": "What is TGTX known for?",
            "answer": "TGTX is known for developing innovative therapies for cancer and autoimmune diseases, particularly its anti-CD20 monoclonal antibody, ublituximab."
        },
        {
            "question": "Who is the CEO of TGTX?",
            "answer": "Dr. Lee Morley is the CEO of TGTX, Inc."
        },
        {
            "question": "Where is TGTX headquartered?",
            "answer": "TGTX is headquartered in Newport Beach, California, USA."
        },
        {
            "question": "What are TGTX's main products?",
            "answer": "TGTX's main products include ublituximab and other pipeline candidates like TG-1701 and TG-1801."
        },
        {
            "question": "When was TGTX founded?",
            "answer": "TGTX was founded in 2010."
        }
    ],
    "competitors": [
        "CLVS",
        "CRSP",
        "JNJ",
        "KITE"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "REGN",
        "VRTX"
    ]
}